The feasibility and early toxicity of radiotherapy with carbogen breathing and nicotinamide was tested in 74 head and neck cancer patients, Forty patients with laryngeal and hypopharyngeal tumors were treated with an accelerated schedule combined with car bogen alone (16) or with carbogen and nicotinamide (24). Thirty-four patients with far advanced unresectable tumors of the oral cavity and oropharynx received conventional radiotherapy with carbogen [16] or with carbogen and nicotinamide (18), Some enhancement of skin reaction was observed with nicotinamide but this remained well within limits of tolerance. With the accelerated regimen there was increased severity of mucosal damage expressed as confluent mucositis in 95% of patients which required healing times of 3 -4 months in four patients. Eventually restoration of the mucosal lining was complete in all cases. Nausea and vomiting are the most frequent side effects of nicotinamide and were reported by 60% and 36% of the subjects, respectively. In 26% this was reason to discontinue drug intake. Severe renal dysfunction was associated with nicotinamide intake in two patients of this study and in one other patient who presented later. It is our conclusion that radiotherapy combined with carbogen and nicotinamide is a safe treatment with manageable side effects. We recommend not to give nicotinamide concomitantly with nephrotoxic medication or to patients who have impaired renal function. Preliminary tumor control rates are encouraging and clini cal testing will be continued.
Introduction
It is well recognized that hypoxia is an important fac tor determining the radiation response o f squamous cell carcinomas. In man, the existence o f hypoxia and its relationship to the outcom e o f radiation therapy has been demonstrated in carcinom as o f the head and neck and uterine cervix [5, 9, 18, 19] . Random ized clinical trials with hyperbaric oxygen and hypoxic cell radiosensitizers have shown significantly improved local control rates in carcinomas o f the head and neck [7, 8, 21, 22] . However, these approaches have not gained general acceptance. The side effects o f many radiosensitizers hamper their clinical use although some newer drugs are less toxic. increase the oxygen partial pressure and reduce chronic hypoxia in patients with head and neck tumors [20] . Relative to radiation treatment in air without the drug, enhancement ratios in the order of 1.8 have been obtain ed for treatment with carbogen and nicotinamide in mouse tumors [17] .
Another important factor determining the radiation response of tumors is cellular repopulation. There is evi dence from clinical studies that patients with head and neck carcinomas may benefit from accelerated frac tionated irradiation to counteract repopulation o f tumor clonogens which occurs during the course o f treatment [1, 26] . Results of randomized trials are expected soon.
Rojas et al. proposed the .strategy of combining accel erated radiotherapy with carbogen and nicotinamide (ARCON) to overcome both the compensating effect o f tumor repopulation and chronic and acute hypoxia [25] . This is a report on the feasibility and toxicity of this approach in patients with carcinomas of the head and neck.
Patients and methods

2.L Design of the study
Two categories of patients were eligible for the study. One category includes patients with laryngeal (stage III-IV) and hypopharyngeal (stage II-IV) tumors receiving primary radiotherapy as larynx conserving treatment. The other category of patients had far ad vanced unresectabel tumors, mostly of the oral cavity and oropharynx and were referred for palliative radiotherapy. It was planned to first treat 15 patients with carbogen alone in each category. After this had been shown to be feasible and without severe direct toxicity, nicotinamide was added. Since experience was previously obtained with an accelerated schedule in laryngeal cancers [13] , it was decided to build on this experience and to add carbogen and nicotinamide as second and third steps, respectively. For the oral cavity and oropharyngeal tumors carbogen breathing and nicotinamide were added stepwise to a conventional radiation schedule. The patients with laryngeal and hypopharyngeal tumors were analyzed separately from those with oral cavity and oropharyngeal tumors because normal tissue effects as well as treatment out come are expected to be different in the two groups.
This work was approved by the local ethical com mittee.
Patients
Seventy-four consecutive patients were entered into the study over the period November 1992 until February 1995. Inclusion criteria were: age over 18 years, WHO performance status o f 0 -2 , no severe heart or lung disease, no severe liver or kidney function disturbances, no severe stridor, no distant metastases, and written in formed consent. Another six patients were eligible but refused participation. Thirteen patients were ineligible for the following reasons: poor performance status (9), severe cardiac and pulmonary disease (4), claustro phobia (1), and Rendu-Osler-W eber disease with severe anemia (1). The patients entered in the study had a mean age o f 57 years (range 2 7 -8 2 years). There were 60 men and 14 women. All patients had squamous cell car cinomas except one with a m ucoepidermoid carcinoma of the larynx. Three patients had two concurrent primary tumors in the head and neck area. Two other patients had recurrent disease after surgical treatment. Characteristics o f the patients, their tumors, and the treatment are shown in Table 1 .
2,5. Radiotherapy
The primary tumor and bilateral neck nodes were irradiated through lateral opposed photon beams (4 and 6 MV). The inferior border was generally placed just superior to the arytenoids for oral cavity and oropharyngeal tumors. For tumors o f larynx and hypopharynx the inferior border was placed just above the shoulders. After 3 0 -4 0 Gy, an off-cord reduction was made and the posterior cervical chains were treated with lateral appositional electron beams. The mid-and lower-neck nodes were treated with an anterior photon field. In some cases a posterior field was added to sup plement the dose in the posterior midcervical chains. 
Site of primary Oral cavity
Oral tongue
No. patients receiving 8 8 --2 chemotherapy aOne patient with synchronous second primary of soft palate (T2). bOne patient with synchronous second primary of pyriform sinus (T2). cOne patient with synchronous second primary of vallecula (Tl).
was combined with carbogen and nicotinamide [6] , total dose to the spinal cord was not higher than 40 Gy. Dose specification was according to Report 29 of the ICRU [12].
2,4, Carbogen breathing
Scuba-diving equipment was used for carbogen deliv ery, This system transports the gas from the reservoir to the patient by way of a two-step pressure reduction. The second stage of the breathing regulator is connected to a disposable anesthetic face mask which is incorporated in the immobilizing cast. Details o f this breathing system have been described earlier [14] . Carbogen breathing commenced 4 min before start of irradiation of the macroscopic tumor localizations and was continued throughout the treatment. During the 4-min pre irradiation breathing time fields were set up and unin volved supraclavicular nodes were treated. Pre irradiation breathing time and total breathing time were recorded.
Nicotinamide
Nicotinamide, dissolved in fruit juice,' was ad ministered orally 1.5 h before irradiations. On days when two fractions were given, only one dose of nicotinamide was taken before the first treatment. In itially the daily dose was 6 g. After April 1994, when more pharmacokinetic data became available, this was changed to a weight-adjusted dose of 80 mg/kg with a maximum of 6 g.
2.6, Monitoring during treatment
Blood pressure and heart rate were measured on the first 5 treatment days just before and after irradiations. This was discontinued after the first 20 patients because no changes had been observed.
Blood samples were drawn once a week for blood cell counting and hemoglobin concentration measurement. When hemoglobin concentrations fell below 7 mmol/1 this was corrected by blood transfusions. Initially, serum liver enzymes, sodium, potassium, urea, and creatinine were determined before and in the last week of the treatment. Later this was also done weekly during the course of irradiation.
Weekly assessment of acute mucosal and skin reac tions started in the first week of treatment and con tinued during treatment and thereafter until the lesions started to heal. Patients were then seen once every 2 or 3 weeks until healing was complete. Reactions of mucosa and skin and dysphagia were scored as shown in Table 2 . Since 1987 this scoring system is applied routinely to all patients receiving radiotherapy to the head and neck area in our institute.
2.7, Additional treatment
Eighteen patients received chemotherapy prior to radiation treatment. In most cases this consisted of cis- Fisher's exact probability test was used to test the significance o f differences in acute toxicity scores between groups. Average durations o f mucosal and skin reactions were compared by the Mest.
Results
L Carbogen breathing
Measurements o f blood pressure and heart rate before and after carbogen breathing were discontinued after no apparent changes were observed in the first 20 patients. 
Nicotinamide
The most common side effects from nicotinamide were nausea and vomiting, reported, respectively, by 25 (60%) and 15 (36%) of the 42 patients taking the drug. Ten patients were nauseous after the first dose of nicotinamide. Often these complaints were unresponsive to anti-emetics including ondansetron. Eleven patients (26%) discontinued the intake o f nicotinamide due to severe nausea and vomiting. One patient was under treatment when adjustments o f nicotinamide dose were made from 6 g to individual weight-corrected doses. In this patient nausea disappeared when the dose was reduced from 6 to 4 g (80 mg/kg). Apart from this one patient we observed no differences in side effects be tween patients taking 6 g and those taking 80 mg/kg. Five patients reported flushing 0 .5 -2 h after ingestion. One patient showed signs o f depression which disap peared within a few days after nicotinamide was discon tinued. One patient refused to continue nicotinamide intake because o f the bad taste. N o serum liver enzyme disturbances related to nicotinamide were observed. Twelve patients had isolated elevation of 7-glutamyl transpeptidase (7 -GT), m ostly already before start of treatment, which was ascribed to alcohol abuse.
Two patients developed severe renal dysfunction following nicotinamide administration. Patient 1 receiv ed daily doses o f 6 
Radiotherapy
Three patients did not complete the planned radiation treatment. One patient died from a massive bleeding in the tumor, one patient developed distant metastases during loco-regional treatment and the third patient as mentioned above had rapid tumor progression, renal complications and deterioration o f general condition. 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 treated by the accelerated schedule only one surpassed the maximum allowed treatment time of 38 days with a single day because of a holiday that was not compen sated for.
Total treatment duration exceeded 48 days in four o f the 34 patients treated according to the conventional sched ule. Reasons were: renal complications (6 days); tracheostomy (1 day); machine breakdown (1 day); holi day, not compensated for (1 day). O f the 40 patients
Early reactions o f mucosa and skin
Scores for acute radiation reactions during and after treatment are shown in Figs. 1 and 2 . Only the highest scores are shown because scores 1 and 2 have limited clinical significance and are nearly always followed by more severe reactions. For the group of patients treated with conventional radiotherapy and carbogen (C) con fluent mucositis occurred in 81% of the cases, and with addition o f nicotinamide (N) this was 83%. Average duration was 3.5 (C) and 5.1 (C+N) weeks {p = 0.08, ttest). The accelerated schedule caused confluent mucositis in all but two cases (95%) with an average duration o f 6.3 (C) and 6.7 (C+N) weeks. Prolonged duration o f confluent mucositis, i.e., persisting more than 6 weeks after the end of treatment, was observed 1 in four patients after the accelerated regimen. In all cases healing was complete within 3 -4 months after treatment. Tube feeding was needed in 29% of patients with oral cavity and oropharynx tumors and in 26% o f patients with laryngeal and hypopharyngeal tumors with no significant differences between patients receiv ing carbogen alone and those receiving carbogen and nicotinamide. Objective and functional mucosal reac tions were not more severe for patients who received chemotherapy prior to irradiation (data not shown).
Addition o f nicotinamide appeared to somewhat increase skin reactions. The conventional schedule with carbogen caused m oist desquamation in four of 16 pa tients (25%) and in 10 o f 18 patients (56%) who received also nicotinamide (p = 0.06, Fisher's exact test), With the accelerated schedule this was nine o f 16 (56%; C) and 15 of 23 (65%; C +N ). Generally the skin healed rapidly within 3 weeks except in one case in which it required 7 weeks. This patient was in the conventional schedule with carbogen and nicotinamide. 
Locoregional tumor control
4, Discussion
Carbogen breathing by the method described previously [14] appears to be feasible and well tolerated, even by patients with large tumors in the upper aerodigestive tract. Only four o f 74 patients were unable to cope with the procedure because they experienced sensa tions o f suffocation, in some cases with hyperventilation which is caused by the carbon dioxide component of the gas. Polarographic 0 2 measurements in metastatic lymph nodes from head and neck carcinomas showed that breathing time before optimal oxygenation was 4 min or less in 19 o f 20 patients [20] . It was also demonstrated that tumor p 0 2 starts to decline after 12-18 min o f carbogen breathing [4] , Thus, irradiations are best delivered between 4 and 15 min after the start of carbogen breathing when tumor oxygenation is at its peak level. This was accomplished in 92% of our radia tion sessions.
Reported side effects o f nicotinamide are: nausea, vomiting, flushing, facial erythema, headache, fatigue, cutaneous reactions, and rare events o f liver toxicity [29] . Doses of nicotinamide o f up to 6 g daily were described as reasonably safe and associated with a low incidence o f side effects. In our experience, with doses of 6 g/day or 80 mg/kg/day, nausea and vomiting occurred frequently and necessitated discontinuation o f the drug in 26%) o f patients. Gastrointestinal symptoms were also reported in other clinical pilot studies: three of six pa tients with head and neck cancer [30] , two of six patients with breast cancer [23] , and in two o f 16 patients with malignant gliomas [28] . The mechanism by which these symptoms are produced is not clear: there may be a sys temic effect or topical irritation o f the gastrointestinal mucosa. In the latter case, an alternative route of admin istration might reduce these unpleasant side effects. Se vere renal dysfunction was associated with nicotinamide intake in two patients. When this article was being finalized a third patient presented with this complica tion, also after previous treatment with cisplatin. Thus, two patients received previous (cisplatin) and one con comitant (ACE-inhibitor, carbasalatcalcium) nephro toxic medication. This, in combination with decreased renal flow due to hypovolem ia as a result o f nicotinamide-induced vom iting and decreased oral fluid intake, may well be the cause o f rapidly developing renal fail ure. Any direct renal toxicity from nicotinamide can, however, not be excluded. It was shown that the drug inhibits renal clearance of 51CrEDTA and l25I-iodohippurate in mice [10] . These effects were dose-related and evident at doses from 400 mg/kg upwards which is considerably higher than the doses clinically applied. Only one previous case of renal toxicity in man has been reported by Zackrisson et al. [30] . This patient received two daily doses of 6 and 3 g. He had a known cardio myopathy and was on treatment with an ACE-inhibitor as was one of our patients. The patient had nausea and vomiting and developed hypotension with elevation of serum creatinine and liver enzymes. Plasma concentra tions of nicotinamide and its metabolites suggested that renal elimination was impaired. Possibly in patients with compromised renal function (nephrotoxic medication, hypovolemia) nicotinamide accumulates in the plasma to a level at which it can aggravate renal dysfunction and may lead to severe renal failure.
Unlike our experience with glioma patients [28], we did not observe nicotinamide-related hepatic toxicity in this category of head and neck cancer patients. One of the patients with renal complications had moderate elevation of liver enzymes but this was unlikely to be re lated to nicotinamide intake because it started 2 weeks after discontinuation o f the drug. Apparently it was the combination with anti-epileptics and steroids that in duced liver toxicity in the glioma patients, Nowadays with the availability o f megavoltage equip ment the incidence of severe skin reactions is low. We previously reported an 8% rate of moist desquamation for conventional radiotherapy with total doses of 68-70 Gy [13] . In this study we observed rates of 25% (C) and 56% (C+N). This increased skin reaction is not unex pected as enhancement ratios of 1.3-1.5 were estimated for rodent skin [17] . With the accelerated schedule alone 50% of patients develop moist desquamation [13] . When carbogen and nicotinamide are added there is only a small further increase to 56% (C) and 65% (C+N) which is not statistically significant. Apart from one case, skin lesions healed rapidly. The early reacting tissue of great er clinical significance is the mucosal membrane. With the conventional schedule, 81% (C) and 83% (C+N) of patients in this study developed confluent mucositis of the oral cavity and oropharynx. This corresponds to the 78% rate that we observed when these areas were treated with radiotherapy alone [15] . Acceleration of treatment causes confluent mucositis in up to 90% of patients with laryngeal cancer, with complete healing within 6 weeks after completion of treatment in all cases [13] . In this study confluent mucositis occurred in 95% of patients (C and C+N). However, four patients had healing times of up to 4 months. A possible increase of severity of mucosal damage by addition of carbogen and nicotinamide may well be expressed as delayed recovery. We believe that the acute radiation toxicity as observed with the current regimen is acceptable but we do not ad vocate further intensification of treatment as this might lead to non-healing lesions and consequential late effects.
In conclusion it is our opinion that radiotherapy combined with carbogen and nicotinamide is a safe treatment with manageable side effects. N o expensive additional equipment is needed and it requires hardly any extra machine time. Certain precautions should be taken, however, especially with regard to nicotinamide administration. We recommend that nicotinamide should not be given to patients presenting with elevated serum creatinine levels and it should not be given con comitantly with nephrotoxic medication. During treat ment, renal function should be monitored at least once a week and twice weekly in patients at risk (e.g., those who were treated previously with cisplatin). Adequate oral intake is demanded. When serum creatinine rises above normal levels, nicotinamide should be discon tinued immediately and proper hydration must be secured, if necessary by intravenous infusion.
Possibly, side effects of nicotinamide can be limited when individual dose adjustments are made or when an alternative route of administration is used. Currently we are monitoring nicotinamide plasma levels in our pa tients to assess whether proper levels are obtained when treatment is given on a day to day routine basis and also to investigate if these are related to the observed side effects.
Preliminary tumor control rates are promising and the approach offers potentials for larynx preservation. In the category of far advanced tumors proposed for palliative treatment, complete regressions were achieved and sustained in a significant proportion of the patients. We expect to increase the effectiveness of the treatment for this particular category with introduction o f the accelerated schedule. Our experience with ARCON so far is encouraging and we will proceed with further clini cal testing.
